Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. Biohaven's experienced management team brings with it a track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia. The company is advancing a pipeline of therapies for diseases, many of which have limited or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia, myostatin inhibition for neuromuscular diseases and metabolic disorders, and brain-penetrant TYK2/JAK1 inhibition for neuroinflammatory disorders. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and targeted extracellular protein degradation platform technology (MoDE™) with potential application in neurological disorders, cancer, and autoimmune diseases.
Company profile
Ticker
BHVN
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Biohaven Research Ltd.
SEC CIK
Corporate docs
Subsidiaries
Biohaven Specialty Pharmaceutical Ltd. • Biohaven Therapeutics Ltd. • Biohaven Pharmaceuticals, Inc. • BioShin Limited • BioShin Hong Kong Limited • BioShin (Shanghai) Consulting Services Co., Limited • Biohaven Bioscience Ireland Limited • Biohaven Therapeutics IP Ltd. • Biohaven CGRP IP Ltd. • BioShin (Singapore) PTE. LTD. ...
Latest filings (excl ownership)
S-8
Registration of securities for employees
9 May 24
8-K
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
9 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Submission of Matters to a Vote of Security Holders
1 May 24
8-K
Other Events
22 Apr 24
424B5
Prospectus supplement for primary offering
19 Apr 24
424B5
Prospectus supplement for primary offering
17 Apr 24
8-K
Regulation FD Disclosure
15 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Mar 24
DEF 14A
Definitive proxy
18 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 125.99 mm | 125.99 mm | 125.99 mm | 125.99 mm | 125.99 mm | 125.99 mm |
Cash burn (monthly) | 25.32 mm | (no burn) | 36.85 mm | 41.47 mm | (no burn) | (no burn) |
Cash used (since last report) | 189.23 mm | n/a | 275.39 mm | 309.90 mm | n/a | n/a |
Cash remaining | -63.24 mm | n/a | -149.40 mm | -183.91 mm | n/a | n/a |
Runway (months of cash) | -2.5 | n/a | -4.1 | -4.4 | n/a | n/a |
Institutional ownership, Q4 2023
53.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 165 |
Opened positions | 39 |
Closed positions | 62 |
Increased positions | 55 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 1.76 tn |
Total shares | 47.05 mm |
Total puts | 38.60 k |
Total calls | 162.90 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
SF Stifel Financial | 6.23 mm | $266.46 bn |
Suvretta Capital Management | 4.57 mm | $195.72 bn |
STT State Street | 3.87 mm | $165.67 bn |
T. Rowe Price | 3.13 mm | $134.15 mm |
RP Management | 2.94 mm | $125.68 bn |
Point72 Asset Management | 2.48 mm | $0.00 |
FMR | 1.93 mm | $82.56 bn |
Perceptive Advisors | 1.73 mm | $73.83 bn |
Vanguard | 1.66 mm | $70.97 bn |
Armistice Capital | 1.50 mm | $64.20 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Apr 24 | Hugin Robert J | Stock Option Common Shares | Grant | Acquire A | No | No | 38.8 | 16,592 | 643.77 k | 16,592 |
30 Apr 24 | Irina Antonijevic | Stock Option Common Shares | Grant | Acquire A | No | No | 38.8 | 16,592 | 643.77 k | 16,592 |
30 Apr 24 | Childs John W | Stock Option Common Shares | Grant | Acquire A | No | No | 38.8 | 16,592 | 643.77 k | 16,592 |
30 Apr 24 | Bailey Gregory | Stock Option Common Shares | Grant | Acquire A | No | No | 38.8 | 16,592 | 643.77 k | 16,592 |
30 Apr 24 | Kishan Mehta | Stock Option Common Shares | Grant | Acquire A | No | No | 38.8 | 16,592 | 643.77 k | 16,592 |
News
Crocs To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
13 May 24
HC Wainwright & Co. Maintains Buy on Biohaven, Lowers Price Target to $59
13 May 24
UBS Maintains Buy on Biohaven, Raises Price Target to $60
23 Apr 24
Cantor Fitzgerald Reiterates Overweight on Biohaven
18 Apr 24
Biohaven Reports Pricing Of Public Offering Of 5.609M Of Its Common Shares At $41 Per Share
18 Apr 24
Press releases
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
22 Apr 24
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
18 Apr 24
Biohaven Announces Proposed Public Offering of Common Shares
17 Apr 24
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
13 Apr 24